Table 2.

Lymphoid bone marrow expansion with rhIL-7 therapy

UPN (age, y)Mature B cellsImmature B cells
CD19+/CD45brightCD19+/CD10CD19+/CD45dimCD19+/CD10+
PrePostPrePostPrePostPrePost
01 (70)0.410.400.280.20
02 (48)42210.410111
03 (67)53431<121
04 (56)6.925.517591055
05 (71)3.52721.911231247
06 (28)4.224.3151.2180.85
08 (20)263517617512280
09 (28)1149.44128138
10 (48)7.3236.646.521739
11 (61)10210266410
12 (62)100.8712726
13 (19)6.91.56.30.74.6334.630
15 (43)14.8110.7119.28011.980
16 (66)323431139
Mean8.077.596.303.196.5123.966.6827.21
Median6.902.05.901.955.3014.504.3010.50
Post-Pre−0.48−3.1117.4620.54
P0.380.0240.00120.0029

NOTE: Summary of bone marrow flow cytometry data. Percentage of bone marrow mononuclear cells for the marker combinations: mature B cells: CD19+/CD45bright and CD19+/CD10; immature B cells: CD19+/CD45dim and CD19+/CD10+. UPN: unique patient number. P value given (Wilcoxon signed rank test) on the absolute difference between “pre” and “post” values for each marker combination.